1191 related articles for article (PubMed ID: 15833844)
21. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
[TBL] [Abstract][Full Text] [Related]
22. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
23. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
24. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
25. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
26. [Carcinogenesis of Barrett's esophagus].
Endo T; Sugawara N; Shinomura Y
Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
[TBL] [Abstract][Full Text] [Related]
27. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
28. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
[TBL] [Abstract][Full Text] [Related]
29. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
30. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
31. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
[TBL] [Abstract][Full Text] [Related]
33. Genomic alterations in malignant transformation of Barrett's esophagus.
Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
[TBL] [Abstract][Full Text] [Related]
34. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
[TBL] [Abstract][Full Text] [Related]
35. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
36. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
Wijnhoven BP; Hussey DJ; Watson DI; Tsykin A; Smith CM; Michael MZ;
Br J Surg; 2010 Jun; 97(6):853-61. PubMed ID: 20301167
[TBL] [Abstract][Full Text] [Related]
38. Decrease in Le(x) expression in esophageal adenocarcinomas arising in Barrett's epithelium.
Engel U; McCombs R; Stranahan P; Pettijohn D; Hage E
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):245-8. PubMed ID: 9107429
[TBL] [Abstract][Full Text] [Related]
39. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
